Inactive Instrument

Press Releases Advaxis, Inc. Nasdaq

Equities

AYLA

US05465V1089

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	Mar. 26	AQ
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	Feb. 20	AQ
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	Feb. 06	AQ
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors	Nov. 06	AQ
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	23-10-23	AQ
Ayala Pharmaceuticals Announces Closing of Merger with Biosight	23-10-19	AQ
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-10	AQ
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023	23-08-01	AQ
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement	23-07-27	AQ
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors	23-07-05	AQ
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	23-06-05	AQ
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	23-05-25	AQ
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update	23-05-23	AQ
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting	23-04-27	AQ
AYALA PHARMACEUTICALS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	23-04-07	AQ
AYALA PHARMACEUTICALS, INC. Financial Statements and Exhibits (form 8-K/A)	23-04-06	AQ
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee	23-03-03	GL
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022	23-02-10	GL
AYALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-02-10	AQ
Advaxis : Certificate of Incorporation/Bylaws - Form 8-K	23-01-30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Advaxis, Inc. Nasdaq

Equities

AYLA

US05465V1089

Press Releases

Filters